LQCL2606 - CMLE - Novel Laboratory-Developed Test for Parkinson Disease Involving Kinetic Amyloid Amplification in Biofluid Specimens

Course Description

LabQ 2026 Clinical Laboratory: Clinical Immunology

Faculty/Authors

Michael A. Metrick II, MD, PhD,
Xander M.R. Van Wijk, PhD
Department of Laboratory Medicine
University of California San Francisco
San Francisco, California

CMLE Credit: 2.0

Estimated Completion Time: 2 hour

Format: Online Educational Activity and Post Exam

Instructions

To claim CMLE credit for the exercise, do the following:

Review the Technical Considerations.
Click Go to Course to view an overview of the modules in this course.
Click Access to begin the course.
Review the Educational Activity.
Complete and submit the Post Exam.
Submit the course Evaluation to register your credit.

Faculty Disclosures
The faculty have no relevant financial relationships with commercial interests to disclose.

Technical Considerations

Release Date: 3/31/2026
Review Date:
Expiration Date: 12/31/2028

Course Objectives

Following completion of this activity, you will be able to

describe common presenting signs and symptoms of Parkinson disease;

list epidemiologic and pathogenic features of Parkinson disease;

describe what laboratory developed tests (LDTs) are (and the regulatory requirements for their validation) in the clinical laboratory; and

describe the theory behind amyloid seed amplification assays and their troubleshooting.

Summary

Availability:

On-Demand

Credit Offered:

2 CMLE Credits